

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Len F. LEE et al.

Serial No.: 10/830,125

Filed: April 23, 2004

For: Novel Benzothiepinines Having Activity as Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake



Atty. Docket No.: 6794A-000032/US/DVD
(3091/04/DIV/2)

Group Art Unit: TBA

Examiner: TBA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
220 20th Street S, Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

January 31, 2005

Sir:

Pursuant to their duty of good faith and candor as set forth in 37 C.F.R. §§ 1.56(a), 1.97 and 1.98 *et seq.*, Applicants submit herewith the attached Form PTO/SB/08A. Applicants submit herewith a copy of each of the references cited for the convenience of the Examiner. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO/SB/08A into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO/SB/08A being initialed and dated by the Examiner.

No fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-0733, as necessary.

Respectfully submitted,

HARNESS, DICKEY, & PIERCE, P.L.C.

By

Ajay Pathak, Reg. No. 38,266

P.O. Box 8910
Reston, Virginia 20195
(703) 668-8000

Enclosure:

Form SB/08A
Cited Documents

JAN 21 2005

PTO/SB/C9A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Sheet 1 of 1

Application Number	10/830,125
Filing Date	April 23, 2004
First Named Inventor	LEE et al.
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	6794A-000032/US/DVD

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1.	US-6,277,831 B1	08/21/2001	Frick et al.	
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	2.	WO 94/09774	05/11/1994			
	3.	WO 98/31225	07/23/1998			
	4.	WO 00 61568	10/19/2000			
	5.	EP 0 818 197 A1	01/14/1998			

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6.	XP-000908990 "Choice of Lipid-Lowering Drugs," <i>The Medical Letter</i> , Vol. 38, No. 980, pp. 67-70 (1996).	
	7.	Japanese Abstract XP 002137557: Banyu Pharm: "Treatment agent for hypercholesterolaemia, hyperlipaemia or arteriosclerosis - contains squalene epoxidase inhibitor and other anti-hyperlipaemic agent," July 13, 1992	
	8.	John R. Crouse, III, "New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug," <i>Coronary Artery Disease</i> , Vol. 7, No. 4, pp. 321-326 (1996).	
	9.	D. Roger Illingworth, "Management of Hyperlipidemia: Goals for the Prevention of Atherosclerosis," <i>Clin. And Investig. Med.</i> , Vol. 13, No. 4, pp. 211-218 (1990).	
	10.	Gustav Schonfeld, "the effects of fibrates on lipoprotein and hemostatic coronary risk factors," <i>Atherosclerosis</i> , Vol. 111, pp. 171-174 (1994).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1460, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1450.

9/13/04